HRP20220133T1 - Optimizirana anti-cd3 bispecifična antitijela i njihove upotrebe - Google Patents
Optimizirana anti-cd3 bispecifična antitijela i njihove upotrebe Download PDFInfo
- Publication number
- HRP20220133T1 HRP20220133T1 HRP20220133TT HRP20220133T HRP20220133T1 HR P20220133 T1 HRP20220133 T1 HR P20220133T1 HR P20220133T T HRP20220133T T HR P20220133TT HR P20220133 T HRP20220133 T HR P20220133T HR P20220133 T1 HRP20220133 T1 HR P20220133T1
- Authority
- HR
- Croatia
- Prior art keywords
- bispecific antibody
- cancer
- antigen
- use according
- cytotoxic
- Prior art date
Links
- 239000000427 antigen Substances 0.000 claims 15
- 108091007433 antigens Proteins 0.000 claims 15
- 102000036639 antigens Human genes 0.000 claims 15
- 231100000433 cytotoxic Toxicity 0.000 claims 12
- 230000001472 cytotoxic effect Effects 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 210000004881 tumor cell Anatomy 0.000 claims 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 2
- 102100027522 Baculoviral IAP repeat-containing protein 7 Human genes 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 2
- 101150029707 ERBB2 gene Proteins 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101000936083 Homo sapiens Baculoviral IAP repeat-containing protein 7 Proteins 0.000 claims 2
- 108010002687 Survivin Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- -1 brc-abl Proteins 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims 1
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 claims 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims 1
- 101800000504 3C-like protease Proteins 0.000 claims 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 claims 1
- 102100036464 Activated RNA polymerase II transcriptional coactivator p15 Human genes 0.000 claims 1
- 102100024003 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 Human genes 0.000 claims 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102000036365 BRCA1 Human genes 0.000 claims 1
- 108700020463 BRCA1 Proteins 0.000 claims 1
- 101150072950 BRCA1 gene Proteins 0.000 claims 1
- 102000015735 Beta-catenin Human genes 0.000 claims 1
- 108060000903 Beta-catenin Proteins 0.000 claims 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 1
- 108700012439 CA9 Proteins 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102100029968 Calreticulin Human genes 0.000 claims 1
- 101800001318 Capsid protein VP4 Proteins 0.000 claims 1
- 102100026548 Caspase-8 Human genes 0.000 claims 1
- 108090000538 Caspase-8 Proteins 0.000 claims 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000008178 Cyclin B1 Human genes 0.000 claims 1
- 108010060385 Cyclin B1 Proteins 0.000 claims 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims 1
- 102100027417 Cytochrome P450 1B1 Human genes 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 108010055196 EphA2 Receptor Proteins 0.000 claims 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 102100035139 Folate receptor alpha Human genes 0.000 claims 1
- 102000003817 Fos-related antigen 1 Human genes 0.000 claims 1
- 108090000123 Fos-related antigen 1 Proteins 0.000 claims 1
- 102100039717 G antigen 1 Human genes 0.000 claims 1
- 102100039554 Galectin-8 Human genes 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 claims 1
- 102000010956 Glypican Human genes 0.000 claims 1
- 108050001154 Glypican Proteins 0.000 claims 1
- 108050007237 Glypican-3 Proteins 0.000 claims 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000793651 Homo sapiens Calreticulin Proteins 0.000 claims 1
- 101000910338 Homo sapiens Carbonic anhydrase 9 Proteins 0.000 claims 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims 1
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 claims 1
- 101000886137 Homo sapiens G antigen 1 Proteins 0.000 claims 1
- 101000608769 Homo sapiens Galectin-8 Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 claims 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims 1
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 claims 1
- 101000628535 Homo sapiens Metalloreductase STEAP2 Proteins 0.000 claims 1
- 101001131670 Homo sapiens PWWP domain-containing DNA repair factor 3A Proteins 0.000 claims 1
- 101000613490 Homo sapiens Paired box protein Pax-3 Proteins 0.000 claims 1
- 101000601724 Homo sapiens Paired box protein Pax-5 Proteins 0.000 claims 1
- 101000691463 Homo sapiens Placenta-specific protein 1 Proteins 0.000 claims 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 1
- 101001123448 Homo sapiens Prolactin receptor Proteins 0.000 claims 1
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 claims 1
- 101000894428 Homo sapiens Transcriptional repressor CTCFL Proteins 0.000 claims 1
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 102100030126 Interferon regulatory factor 4 Human genes 0.000 claims 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 claims 1
- 101150059949 MUC4 gene Proteins 0.000 claims 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 1
- 102000003735 Mesothelin Human genes 0.000 claims 1
- 108090000015 Mesothelin Proteins 0.000 claims 1
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 claims 1
- 102100026711 Metalloreductase STEAP2 Human genes 0.000 claims 1
- 101150058357 Muc2 gene Proteins 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 claims 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 108060006580 PRAME Proteins 0.000 claims 1
- 102000036673 PRAME Human genes 0.000 claims 1
- 102100040891 Paired box protein Pax-3 Human genes 0.000 claims 1
- 102100037504 Paired box protein Pax-5 Human genes 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 102100026181 Placenta-specific protein 1 Human genes 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 1
- 102100029000 Prolactin receptor Human genes 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 claims 1
- 102100037421 Regulator of G-protein signaling 5 Human genes 0.000 claims 1
- 101710140403 Regulator of G-protein signaling 5 Proteins 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 claims 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 claims 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 claims 1
- 101710185775 Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 102100021393 Transcriptional repressor CTCFL Human genes 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 claims 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 102100027244 U4/U6.U5 tri-snRNP-associated protein 1 Human genes 0.000 claims 1
- 101710155955 U4/U6.U5 tri-snRNP-associated protein 1 Proteins 0.000 claims 1
- 102000015979 Uroplakin-3 Human genes 0.000 claims 1
- 108050004262 Uroplakin-3 Proteins 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000022534 cell killing Effects 0.000 claims 1
- 201000010240 chromophobe renal cell carcinoma Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000024596 kidney oncocytoma Diseases 0.000 claims 1
- 208000006178 malignant mesothelioma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 101800000607 p15 Proteins 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000016914 ras Proteins Human genes 0.000 claims 1
- 108010014186 ras Proteins Proteins 0.000 claims 1
- 208000005039 renal oncocytoma Diseases 0.000 claims 1
- 208000000649 small cell carcinoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 208000017572 squamous cell neoplasm Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 206010042863 synovial sarcoma Diseases 0.000 claims 1
- 101150047061 tag-72 gene Proteins 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 101150065732 tir gene Proteins 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 230000005909 tumor killing Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 208000023747 urothelial carcinoma Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (15)
1. Citotoksično bispecifično antitijelo za upotrebu u liječenju raka kod subjekta, gdje se bispecifično antitijelo sastoji iz prvog kraka koji vezuje antigen koji očituje slabo do nedetektibilno vezivanje za humani CD3 i CD3 cinomolgusa, i drugog kraka koji vezuje antigen koji se veže za antigen koji je povezan sa tumorom, pri čemu se svaki od prvog kraka koji vezuje antigen i drugog kraka koji vezuje antigen sastoji iz teškog lanca i lakog lanca, pri čemu je laki lanac zajednički za oba, prvi krak koji vezuje antigen i drugi krak koji vezuje antigen, i pri čemu težak lanac prvog kraka koji vezuje antigen sadrži varijabilni dio teškog lanca (HCVR) koji se sastoji iz dijela koji određuju komplementarnost HCDR1, HCDR2 i HCDR3 koji se sastoje iz aminokiselinskih sekvenci, redom, SEQ ID NOs: 36, 38, i 40 SEQ ID NOs: 140, 142 i 144.
2. Citotoksično bispecifično antitijelo za upotrebu prema zahtjevu 1, pri čemu bispecifično antitijelo očituje aktivaciju T stanica in vitro.
3. Citotoksično bispecifično antitijelo za upotrebu prema zahtjevu 1 ili 2, pri čemu je antigen povezan sa tumorom izražen na humanoj tumorskoj stanici.
4. Citotoksično bispecifično antitijelo za upotrebu prema bilo kojem od zahtjeva 1-3, gdje bispecifično antitijelo inducira ubijanje tumorskih stanica posredstvom T stanica sa vrijednošću EC50 manjom od oko 1.3 nM, kao što je mjereno u in vitro testu ubijanja tumorskih stanica posredstvom T stanica.
5. Citotoksično bispecifično antitijelo za upotrebu prema bilo kojem od zahtjeva 1-4, pri čemu ciljna stanica tumora izražava antigen povezan sa tumorom izabran iz grupe koja se sastoji iz AFP, ALK, BAGE proteina, BIRC5 (survivin), BIRC7, β-katenina, brc-abl, BRCA1, BORIS, CA9, karbonatne dehidrataze IX, kaspaza-8, CALR, CCR5, CD19, CD20 (MS4A1), CD22, CD30, CD40, CDK4, CEA, CTLA4, ciklin-B1, CYP1B1, EGFR, EGFRvIII, ErbB2/Her2, ErbB3, ErbB4, ETV6-AML, EpCAM, EphA2, Fra-1, FOLR1, GAGE proteina (npr., GAGE-1, -2), GD2, GD3, GloboH, glipikan-3, GM3, gp100, Her2, HLA/B-raf, HLA/k-ras, HLA/MAGE-A3, hTERT, LMP2, MAGE proteina (npr., MAGE-1, -2, -3, -4, -6, i -12), MART-1, mezotelina, ML-IAP, Muc1, Muc2, Muc3, Muc4, Muc5, Muc16 (CA-125), MUM1, NA17, NY-BR1, NY-BR62, NY-BR85, NY-ESO1, OX40, p15, p53, PAP, PAX3, PAX5, PCTA-1, PLAC1, PRLR, PRAME, PSMA (FOLH1), RAGE proteina, Ras, RGS5, Rho, SART-1, SART-3, STEAP1, STEAP2, TAG-72, TGF-β, TMPRSS2, Thompson-nouvelle antigena (Tn), TRP-1, TRP-2, tirozinaze, i uroplakina-3.
6. Citotoksično bispecifično antitijelo za upotrebu prema bilo kojem od zahtjeva 1-5, pri čemu se laki lanac sastoji od varijabilnog dijela lakog lanca (LCVR) koji se sastoji od područja koji određuju komplementarnost LCDR1, LCDR2 i LCDR3 koji se sastoje iz aminokiselinskih sekvenci, redom, SEQ ID NOs: 164, 166 i 168.
7. Citotoksično bispecifično antitijelo za upotrebu prema zahtjevu 6, gdje LCVR sadrži aminokiselinsku sekvencu SEQ ID NO: 162.
8. Citotoksično bispecifično antitijelo za upotrebu prema bilo kojem od zahtjeva 1-5, pri čemu je laki lanac srodni laki lanac teškog lanca drugog kraka koji se vezuje za antigen koji vezuje antigen povezan sa tumorom.
9. Citotoksično bispecifično antitijelo za upotrebu prema zahtjevu 6, gdje prvi krak koji vezuje antigen sadrži područja koja određuju komplementarnost HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 i LCDR3 koji se sastoje iz aminokiselinskih sekvenci, redom, SEQ ID NOs: 36, 38, 40, 164, 166 i 168.
10. Citotoksično bispecifično antitijelo za upotrebu prema zahtjevu 6, gdje prvi krak koji vezuje antigen sadrži područja koja određuju komplementarnost HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 i LCDR3 koji se sastoje iz aminokiselinskih sekvenci, redom, SEQ ID NOs: 140, 142, 144, 164, 166 i 168.
11. Citotoksično bispecifično antitijelo za upotrebu prema zahtjevu 7, gdje bispecifično antitijelo sadrži par HCVR i LCVR aminokiselinskih sekvenci (HCVR/LCVR) koje se sastoje iz aminokiselinskih sekvenci SEQ ID NOs: 34/162.
12. Citotoksično bispecifično antitijelo za upotrebu prema zahtjevu 7, gdje bispecifično antitijelo sadrži par HCVR and LCVR aminokiselinskih sekvenci (HCVR/LCVR) koje se sastoje iz aminokiselinskih sekvenci SEQ ID NOs: 138/162.
13. Farmaceutski sastav koji se sastoji iz (i) bispecifičnog antitijela prema bilo kojem od zahtjeva 1-12, i (ii) farmaceutski prihvatljivog nosača ili razblaživača.
14. Farmaceutski sastav prema zahtjevu 13 za upotrebu u postupku liječenja raka kod subjekta, postupak obuhvaća davanje subjektu farmaceutskog sastava.
15. Farmaceutski sastav za upotrebu prema zahtjevu 14, pri čemu je rak izabran iz grupe koja se sastoji iz: raka gušterače, melanoma, glioblastoma, raka glave i vrata, raka prostate, malignih glioma, osteosarkoma, kolorektalnog raka, raka želuca, malignog mezotelioma, multiplog mijeloma, raka jajnika, raka malih stanica pluća, raka ne-malih stanica pluća, sinovijalnog sarkoma, raka tireoidee, raka dojke, melanoma glioma, raka dojke, raka skvamoznih stanica, raka jednjaka, raka bubrežnih bistrih stanica, kromofobnog raka stanica bubrega, onkocitoma bubrega, prijelaznog raka stanica bubrega, urotelnog karcinoma, adenokarcinoma, ili karcinoma malih stanica, opcionalno kada je subjekt pogođen sa tumorom koji je otporan na, ili nepotpuno reagira samo na monspecifičnu terapiju.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562222605P | 2015-09-23 | 2015-09-23 | |
PCT/US2016/053525 WO2017053856A1 (en) | 2015-09-23 | 2016-09-23 | Optimized anti-cd3 bispecific antibodies and uses thereof |
EP16781236.1A EP3353212B1 (en) | 2015-09-23 | 2016-09-23 | Optimized anti-cd3 bispecific antibodies and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20220133T1 true HRP20220133T1 (hr) | 2022-04-15 |
HRP20220133T8 HRP20220133T8 (hr) | 2022-05-13 |
Family
ID=57130447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20220133TT HRP20220133T8 (hr) | 2015-09-23 | 2016-09-23 | Optimizirana anti-cd3 bispecifična antitijela i njihove upotrebe |
Country Status (28)
Country | Link |
---|---|
US (2) | US20180355038A1 (hr) |
EP (1) | EP3353212B1 (hr) |
JP (3) | JP7023231B2 (hr) |
KR (1) | KR20180050412A (hr) |
CN (1) | CN108290951B (hr) |
AU (1) | AU2016325630B2 (hr) |
BR (1) | BR112018005445A2 (hr) |
CA (1) | CA2999385A1 (hr) |
CY (1) | CY1124944T1 (hr) |
DK (1) | DK3353212T3 (hr) |
EA (1) | EA201890785A1 (hr) |
ES (1) | ES2901133T3 (hr) |
HK (1) | HK1258304A1 (hr) |
HR (1) | HRP20220133T8 (hr) |
HU (1) | HUE057683T2 (hr) |
IL (1) | IL258036B (hr) |
LT (1) | LT3353212T (hr) |
MA (1) | MA42935B1 (hr) |
MD (1) | MD3353212T2 (hr) |
MX (1) | MX2018003403A (hr) |
MY (1) | MY195059A (hr) |
PL (1) | PL3353212T3 (hr) |
PT (1) | PT3353212T (hr) |
RS (1) | RS62859B1 (hr) |
SI (1) | SI3353212T1 (hr) |
TW (2) | TWI783914B (hr) |
WO (1) | WO2017053856A1 (hr) |
ZA (1) | ZA201801673B (hr) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
PL3221359T3 (pl) | 2014-11-17 | 2020-11-16 | Regeneron Pharmaceuticals, Inc. | Sposoby leczenia nowotworów przy użyciu dwuswoistego przeciwciała CD3XCD20 |
EP3277725B1 (en) | 2015-03-30 | 2020-11-25 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
AU2016267691B2 (en) * | 2015-05-28 | 2022-06-16 | Genentech, Inc. | Cell-based assay for detecting anti-CD3 homodimers |
TW202340452A (zh) | 2015-08-04 | 2023-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
US11530277B2 (en) | 2016-04-20 | 2022-12-20 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
AR109451A1 (es) | 2016-04-20 | 2018-12-12 | Regeneron Pharma | Composiciones y métodos para preparar anticuerpos basados en el uso de loci mejoradores de expresión |
BR112019005670A2 (pt) | 2016-09-23 | 2019-06-04 | Regeneron Pharma | anticorpos anti-muc16 (mucina 16) |
EP3409322A1 (en) | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
TWI789399B (zh) * | 2017-06-22 | 2023-01-11 | 財團法人生物技術開發中心 | 不對稱異二聚fc-scfv融合抗globo h及抗cd3雙特異性抗體及其於癌症治療上之用途 |
EA201990784A1 (ru) * | 2017-09-14 | 2019-09-30 | Ридженерон Фармасьютикалз, Инк. | Анти-muc16 (mucin16) антитела |
KR20200058525A (ko) * | 2017-09-29 | 2020-05-27 | 리제너론 파아마슈티컬스, 인크. | 스타필로코커스 표적 항원 및 보체 성분에 결합하는 이특이적 항원-결합 분자 및 이의 용도 |
WO2019133761A1 (en) * | 2017-12-27 | 2019-07-04 | Teneobio, Inc. | Cd3-delta/epsilon heterodimer specific antibodies |
AU2019290198A1 (en) | 2018-06-21 | 2021-01-14 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-PSMA x anti-CD28 antibodies and uses thereof |
TW202005985A (zh) * | 2018-06-21 | 2020-02-01 | 美商再生元醫藥公司 | 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法 |
JOP20200343A1 (ar) | 2018-07-02 | 2020-12-31 | Xencor Inc | بروتين ربط مولد ضد مضاد لـ steap1 |
KR20210034032A (ko) | 2018-07-19 | 2021-03-29 | 리제너론 파아마슈티컬스, 인크. | 이중특이적 항-BCMA x 항-CD3 항체 및 이의 용도 |
KR20210049863A (ko) | 2018-08-23 | 2021-05-06 | 리제너론 파아마슈티컬스, 인크. | 항-Fc 엡실론-R1 알파 (FCERIA) 항체, FCERIA 및 CD3에 결합하는 이중특이적 항원-결합 분자 및 이들의 용도 |
AU2019331024A1 (en) | 2018-08-31 | 2021-03-18 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for CD3/C20 bispecific antibodies |
EP3864049A1 (en) | 2018-10-11 | 2021-08-18 | Inhibrx, Inc. | Pd-1 single domain antibodies and therapeutic compositions thereof |
TW202028246A (zh) | 2018-10-11 | 2020-08-01 | 美商英伊布里克斯公司 | B7h3單域抗體及其治療性組合物 |
JP2022504822A (ja) | 2018-10-11 | 2022-01-13 | インヒブルクス インコーポレイテッド | Dll3シングルドメイン抗体およびその治療用組成物 |
WO2020076992A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | 5t4 single domain antibodies and therapeutic compositions thereof |
CA3121842A1 (en) * | 2018-12-04 | 2020-03-19 | Novartis Ag | Binding molecules against cd3 and uses thereof |
CA3121565A1 (en) * | 2018-12-07 | 2020-06-11 | Jiangsu Hengrui Medicine Co., Ltd. | Cd3 antibody and pharmaceutical use thereof |
SG11202105948TA (en) | 2018-12-19 | 2021-07-29 | Regeneron Pharma | Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof |
AU2019405747A1 (en) | 2018-12-19 | 2021-06-17 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-CD28 x anti-CD22 antibodies and uses thereof |
CA3134335A1 (en) | 2019-03-22 | 2020-10-01 | Regeneron Pharmaceuticals, Inc. | Egfr x cd28 multispecific antibodies |
AU2020296181A1 (en) * | 2019-06-21 | 2021-12-16 | Regeneron Pharmaceuticals, Inc. | Use of bispecific antigen-binding molecules that bind PSMA and CD3 in combination with 4-1BB co-stimulation |
WO2021006199A1 (ja) | 2019-07-05 | 2021-01-14 | 小野薬品工業株式会社 | Pd-1/cd3二重特異性タンパク質による血液がん治療 |
BR112022002012A2 (pt) | 2019-08-15 | 2022-06-07 | Regeneron Pharma | Moléculas multispecíficas de ligação a antígeno para células-alvo e usos das mesma |
CN110551222B (zh) * | 2019-08-27 | 2023-06-06 | 重庆市畜牧科学院 | 一种新型双功能抗体及其用途 |
EP4069373A1 (en) | 2019-12-06 | 2022-10-12 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bispecific anti-bcma x anti-cd3 antibodies |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
EP4214233A1 (en) | 2020-09-16 | 2023-07-26 | Amgen Inc. | Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer |
CN116963774A (zh) | 2021-01-28 | 2023-10-27 | 瑞泽恩制药公司 | 用于治疗细胞因子释放综合征的组合物和方法 |
IL308257A (en) | 2021-05-05 | 2024-01-01 | Immatics Biotechnologies Gmbh | Antigen binding proteins that uniquely bind PRAME |
WO2023097219A2 (en) * | 2021-11-24 | 2023-06-01 | Adimab, Llc | Anti-idiotype antibodies |
TW202346337A (zh) | 2022-03-29 | 2023-12-01 | 美商恩格姆生物製藥公司 | Ilt3及cd3結合劑以及其使用方法 |
US20230357446A1 (en) | 2022-04-11 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
CN114685675B (zh) * | 2022-04-27 | 2023-02-03 | 深圳市汉科生物工程有限公司 | 双特异性抗体及其在治疗癌症中的用途 |
WO2024012513A1 (en) * | 2022-07-13 | 2024-01-18 | Hansoh Bio Llc | Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof |
WO2024077044A1 (en) | 2022-10-05 | 2024-04-11 | Amgen Inc. | Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof |
WO2024081180A1 (en) | 2022-10-10 | 2024-04-18 | Regeneron Pharmaceuticals, Inc. | Methods for reducing alloantibody levels in subjects in need of solid organ transplantation |
WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
CA2461631A1 (en) * | 2001-09-28 | 2003-04-03 | Elusys Therapeutics, Inc. | Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules |
US7820166B2 (en) | 2002-10-11 | 2010-10-26 | Micromet Ag | Potent T cell modulating molecules |
SI1629011T1 (sl) | 2003-05-31 | 2010-05-31 | Micromet Ag | Humane molekule za vezavo anti hu cd |
EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
CN102875681A (zh) * | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
JP2012508022A (ja) * | 2008-11-06 | 2012-04-05 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 減少した免疫原性を有する操作された抗体および作製方法 |
JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
WO2011056997A1 (en) | 2009-11-04 | 2011-05-12 | Fabrus Llc | Methods for affinity maturation-based antibody optimization |
ES2603559T5 (es) | 2010-02-08 | 2021-02-22 | Regeneron Pharma | Cadena ligera común de ratón |
PL3339323T3 (pl) * | 2010-08-12 | 2020-05-18 | Eli Lilly And Company | Przeciwciała przeciwko peptydowi N3pGlu amyloidu beta i ich zastosowania |
CN107586340B (zh) * | 2011-08-23 | 2022-01-21 | 罗切格利卡特公司 | 对t细胞活化性抗原和肿瘤抗原特异性的双特异性抗体及使用方法 |
WO2013157105A1 (ja) * | 2012-04-18 | 2013-10-24 | 公立大学法人大阪市立大学 | ムチンサブタイプ5ac特異的ヒト化抗体およびその利用 |
WO2013184761A1 (en) * | 2012-06-05 | 2013-12-12 | Regeneron Pharmaceuticals, Inc. | Methods for making fully human bispecific antibodies using a common light chain |
JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
SI2900694T1 (sl) * | 2012-09-27 | 2018-12-31 | Merus N.V. | Bispecifična IGG protitelesa kot vključitelji T-celic |
EP2904016B1 (en) * | 2012-10-08 | 2018-11-14 | Roche Glycart AG | Fc-free antibodies comprising two fab-fragments and methods of use |
TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
JP6510532B2 (ja) * | 2013-12-20 | 2019-05-08 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性her2抗体及び使用方法 |
TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
JOP20160154B1 (ar) * | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
-
2016
- 2016-09-23 MX MX2018003403A patent/MX2018003403A/es unknown
- 2016-09-23 CN CN201680068487.4A patent/CN108290951B/zh active Active
- 2016-09-23 JP JP2018534519A patent/JP7023231B2/ja active Active
- 2016-09-23 SI SI201631414T patent/SI3353212T1/sl unknown
- 2016-09-23 LT LTEPPCT/US2016/053525T patent/LT3353212T/lt unknown
- 2016-09-23 DK DK16781236.1T patent/DK3353212T3/da active
- 2016-09-23 AU AU2016325630A patent/AU2016325630B2/en active Active
- 2016-09-23 WO PCT/US2016/053525 patent/WO2017053856A1/en active Application Filing
- 2016-09-23 TW TW105130880A patent/TWI783914B/zh active
- 2016-09-23 HR HRP20220133TT patent/HRP20220133T8/hr unknown
- 2016-09-23 EA EA201890785A patent/EA201890785A1/ru unknown
- 2016-09-23 EP EP16781236.1A patent/EP3353212B1/en active Active
- 2016-09-23 MD MDE20180740T patent/MD3353212T2/ro unknown
- 2016-09-23 HU HUE16781236A patent/HUE057683T2/hu unknown
- 2016-09-23 PL PL16781236T patent/PL3353212T3/pl unknown
- 2016-09-23 MY MYPI2018700990A patent/MY195059A/en unknown
- 2016-09-23 PT PT167812361T patent/PT3353212T/pt unknown
- 2016-09-23 ES ES16781236T patent/ES2901133T3/es active Active
- 2016-09-23 IL IL258036A patent/IL258036B/en unknown
- 2016-09-23 KR KR1020187011246A patent/KR20180050412A/ko not_active Application Discontinuation
- 2016-09-23 TW TW111122347A patent/TWI784917B/zh active
- 2016-09-23 RS RS20220089A patent/RS62859B1/sr unknown
- 2016-09-23 MA MA42935A patent/MA42935B1/fr unknown
- 2016-09-23 BR BR112018005445A patent/BR112018005445A2/pt active Search and Examination
- 2016-09-23 CA CA2999385A patent/CA2999385A1/en active Pending
- 2016-09-23 US US15/780,504 patent/US20180355038A1/en not_active Abandoned
-
2018
- 2018-03-12 ZA ZA2018/01673A patent/ZA201801673B/en unknown
-
2019
- 2019-01-15 HK HK19100669.9A patent/HK1258304A1/zh unknown
-
2021
- 2021-03-19 US US17/207,462 patent/US20210253701A1/en active Pending
- 2021-12-27 JP JP2021211788A patent/JP2022064886A/ja active Pending
-
2022
- 2022-02-02 CY CY20221100087T patent/CY1124944T1/el unknown
-
2023
- 2023-08-10 JP JP2023130597A patent/JP2023154021A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20220133T1 (hr) | Optimizirana anti-cd3 bispecifična antitijela i njihove upotrebe | |
JP2018537516A5 (hr) | ||
FI3459597T3 (fi) | Yksiketjuinen vasta-aine ctla4:lle ja siitä johdettu proteiini | |
JP2018524358A5 (hr) | ||
HRP20211710T1 (hr) | Konjugacija specifična za mjesto spajanja lijekova za povezivanje s protutijelima i konjugati protutijela u lijeku koji nastaje kao rezultat | |
PH12019500603A1 (en) | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof | |
JP2020506971A5 (hr) | ||
RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
BR112019005697A2 (pt) | anticorpos anti-muc16-cd3 biespecíficos e conjugados de fármaco e anti-muc16 | |
JP2020500538A5 (hr) | ||
RU2013128444A (ru) | Новые модуляторы и способы их применения | |
EA201890294A1 (ru) | Химерный полипептидный комплекс и способы его получения и применения | |
FI3303396T3 (fi) | Vasta-aineita ox40:ää vastaan ja niiden käyttöjä | |
RU2017105915A (ru) | Антитела против pd-1 | |
JP2018522564A5 (hr) | ||
JP2017506217A5 (hr) | ||
WO2017007796A4 (en) | Multispecific antigen-binding molecules and uses thereof | |
RU2017108203A (ru) | Слитые белки sirp-альфа с иммуноглобулином | |
RU2014106671A (ru) | Варианты гуманизированных иммуномодулирующих моноклональных антител | |
RU2016122041A (ru) | Новые анти-клаудин антитела и способы их применения | |
RU2017117596A (ru) | Связывающие молекулы, специфичные в отношении CD73, и пути их применения | |
JP2017510559A5 (hr) | ||
JP2017510661A5 (hr) | ||
RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
WO2017060322A3 (en) | Ptefb-inhibitor-adc |